Delving into the Latest Updates on BEBT-209 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

CDK4 x CDK6

Mechanism

CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Hormone receptor positive HER2 negative breast cancerAdvanced Triple-Negative Breast CarcinomaAdvanced breast cancer+ [2]

Inactive Indication-

Originator Organization

BeBetter Med, Inc.

Active Organization

BeBetter Med, Inc.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

主要目的：评估BEBT-209联合系统化疗（卡铂和吉西他滨、白蛋白结合型紫杉醇或艾立布林）治疗晚期三阴性乳腺癌的安全性和初步疗效。次要目的：探索BEBT-209联合系统化疗治疗晚期三阴性乳腺癌的药效学与肿瘤组织表达PD-L1之关系。

[Translation]

Primary objective: To evaluate the safety and preliminary efficacy of BEBT-209 combined with systemic chemotherapy (carboplatin and gemcitabine, albumin-bound paclitaxel or eribulin) in the treatment of advanced triple-negative breast cancer. Secondary objective: To explore the relationship between the pharmacodynamics of BEBT-209 combined with systemic chemotherapy in the treatment of advanced triple-negative breast cancer and the expression of PD-L1 in tumor tissues.

Start Date03 Apr 2023

Sponsor / Collaborator

BeBetter Med, Inc.

ChiCTR2200059458 / SuspendedPhase 3IIT

A Multicenter, Randomized, Controlled, Double-Blind Phase III Study of BEBT-209 in Combination with Fulvestrant Versus Placebo in Combination with Fulvestrant for the Treatment of HR-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Start Date01 Jun 2022

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

100 Clinical Results associated with BEBT-209

Login to view more data

100 Translational Medicine associated with BEBT-209

Login to view more data

100 Patents (Medical) associated with BEBT-209

Login to view more data

100 Deals associated with BEBT-209

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone receptor positive HER2 negative breast cancer	Phase 3	CN	BeBetter Med, Inc.	23 May 2022
Advanced Triple-Negative Breast Carcinoma	Phase 2	CN	BeBetter Med, Inc.	03 Apr 2023
Advanced breast cancer	Phase 1	CN	BeBetter Med, Inc.	15 Jul 2019
Estrogen receptor positive breast cancer	Phase 1	CN	BeBetter Med, Inc.	15 Jul 2019
HER2-negative breast cancer	Phase 1	CN	BeBetter Med, Inc.	15 Jul 2019